Algernon Pharmaceuticals Inc.
AGN
CNSX
| 11/30/2024 | 08/31/2024 | 05/31/2024 | 02/29/2024 | 11/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 93.25% | 92.52% | 59.65% | 17.42% | 22.27% |
| Total Depreciation and Amortization | -47.08% | -48.00% | -48.28% | -26.27% | -4.47% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -169.49% | -154.53% | -94.56% | 61.83% | 101.93% |
| Change in Net Operating Assets | -171.94% | -147.39% | -107.03% | 24.35% | -21.25% |
| Cash from Operations | -59.44% | -4.94% | 24.95% | 57.61% | 57.51% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 5,513.92% | 3,893.42% | 2,243.08% | 37.99% | 67.47% |
| Cash from Investing | 5,513.92% | 3,893.42% | 2,243.08% | 37.99% | 67.47% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -46.83% | -51.19% | -84.72% | 3.25% | -15.49% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 312.23% | 312.23% | -75.08% | -88.12% | -91.20% |
| Cash from Financing | -27.02% | -32.71% | -82.94% | -32.59% | -45.70% |
| Foreign Exchange rate Adjustments | 333.33% | -300.00% | 200.00% | -118.75% | -109.84% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 145.70% | 136.20% | 140.14% | 90.86% | 70.41% |